Evoke Pharma INC 8-K filings

Evoke Pharma, Inc. has completed its acquisition by QOL Medical, LLC, becoming a wholly-owned subsidiary and delisting from Nasdaq.

Evoke Pharma announced its acquisition by QOL Medical for $11.00 per share in cash, alongside reporting a 61% year-over-year increase in third-quarter net product sales.

Evoke Pharma has entered into a definitive agreement to be acquired by QOL Medical for $11.00 per share in cash, representing a 139.7% premium.

Evoke Pharma reported a 47% year-over-year increase in GIMOTI net product sales for Q2 2025, reaching $3.8 million, and confirmed its full-year 2025 revenue guidance of $16 million.

Evoke Pharma announced the issuance of a new U.S. patent for its product GIMOTI, extending intellectual property protection until November 2038.

Evoke Pharma, Inc. announced it has received a Notice of Allowance for a U.S. patent application covering GIMOTI, extending its market exclusivity for the gastroparesis treatment until December 2036.

Evoke Pharma held its annual meeting on May 21, 2025, and stockholders voted on the election of directors, ratification of auditors, and executive compensation.

Evoke Pharma announces a 77% year-over-year increase in net product sales for Q1 2025, driven by growing prescriber adoption of GIMOTI.

Evoke Pharma announces a 97.8% year-over-year revenue increase for 2024, driven by strong commercial execution and expanded patient access to GIMOTI.

Evoke Pharma appoints Greg Pyszcymuka to its Board of Directors, effective immediately, with an initial term expiring at the 2026 annual meeting.

Evoke Pharma announced its highest ever quarterly revenue of $2.7 million for GIMOTI in Q3 2024, marking a 70% year-over-year increase.

Evoke Pharma announced study results showing GIMOTI nasal spray significantly reduced healthcare resource utilization in diabetic gastroparesis patients also using GLP-1 agonists compared to oral metoclopramide.

Evoke Pharma has appointed Benjamin Smeal to its Board of Directors, effective October 18, 2024, leading to a reshuffling of the company's key committees.

Evoke Pharma has extended its headquarters lease agreement to March 31, 2027, with a new rent schedule and a one-month rent abatement.

Evoke Pharma has amended its warrants with Nantahala Capital Management affiliates, reducing exercise prices and securing approximately $2.4 million in gross proceeds, while also granting board representation rights to Nantahala.

Evoke Pharma has successfully regained compliance with Nasdaq's minimum bid price requirement, resolving a previous non-compliance issue.

Evoke Pharma's GIMOTI nasal spray saw a 47% quarter-over-quarter and 126% year-over-year increase in net product sales, reaching a record high in prescription fills during the second quarter of 2024.

Evoke Pharma has executed a 1-for-12 reverse stock split, effective August 1, 2024, to increase its share price and maintain Nasdaq listing compliance.

Evoke Pharma has amended its Series A, B, and C warrants, allowing holders to opt for pre-funded warrants and accelerating the vesting of Series C warrants under certain conditions.

Evoke Pharma has regained compliance with Nasdaq's minimum stockholders' equity requirement but will be subject to a one-year monitoring period.

Evoke Pharma announced the appointment of Mark A. Kowieski as Chief Financial Officer, an increase in authorized shares, and the approval of an amended equity incentive plan at its annual meeting.

Evoke Pharma announced a 114% year-over-year increase in net product sales for Q1 2024, driven by a 70% growth in prescribers, despite facing challenges from a cyberattack and increased co-pay expenses.

Evoke Pharma has determined that its previously issued financial statements for 2023 and certain quarterly reports should no longer be relied upon due to a misclassification of debt.

Evoke Pharma has amended its Series A, B, and C warrants, offering holders the option to receive pre-funded warrants and adjusting the vesting schedule for Series C warrants based on the exercise of Series B warrants by a specific deadline.

Evoke Pharma has appointed Matthew J. D'Onofrio as its new CEO, effective March 31, 2024, succeeding Dave A. Gonyer who is resigning for personal reasons.

Evoke Pharma has been granted an extension to maintain its Nasdaq listing, contingent on demonstrating compliance with minimum equity requirements by May 15, 2024.

Evoke Pharma announced a 107% increase in net product sales for 2023, reaching $5.2 million, and projects $14 million in net revenue for 2024.

Evoke Pharma has been notified by Nasdaq that its stock price has fallen below the minimum $1.00 per share requirement for continued listing.

Evoke Pharma issued warrants to underwriters as part of a recent offering, allowing them to purchase shares at $1.122 each, exercisable after six months and expiring in five years.

Evoke Pharma has announced a public offering to raise up to $30 million, including an initial $7.5 million, to fund working capital and general corporate purposes.